Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00180479 · ClinicalTrials.gov registry record · Phase 3
SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
A Phase 3 study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,002
- Enrollment target
NCT00180479: Completed Phase 3 study, sponsored by Abbott Medical Devices.
NCT00180479 is a Phase 3 study that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,002 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00180479, a Phase 3 study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,002 participants
- Enrollment target
Study Summary
This study is divided into 5 arms: 1. Randomized Clinical Trial (RCT): Prospective, randomized, active-controlled, single blind, parallel two-arm multi-center clinical trial in the United States (US) comparing XIENCE V® Everolimus Eluting Coronary Stent System (CSS) (2.5, 3.0, 3.5 mm diameter stents) to the Food and Drug Administration (FDA) approved commercially available active control TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent (TAXUS® EXPRESS2™ PECS) System 2. US 2.25 mm non-randomized arm using 2.25 mm diameter XIENCE V® Everolimus Eluting CSS 3. US 4.0 mm non-randomized arm using 4.0 mm diameter XIENCE V® Everolimus Eluting CSS 4. US 38 mm non-randomized arm using 38 mm in length XIENCE V® Everolimus Eluting CSS 5. Japanese non-randomized arm using XIENCE V® Everolimus Eluting CSS (2.5, 3.0, 3.5, 4.0 mm diameter stents) in Japan The TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System is Manufactured by Boston Scientific.
Primary Outcome
In-segment minimal lumen diameter (MLD) post-procedure minus (-) in segment MLD at 240 day follow-up and 5 mm proximal and 5mm distal to the stent equals Late Loss. MLD defined: The average of two orthogonal views (when possible) of the narrowest point within the area of assessment.
Interventions
- DEVICE XIENCE V® Everolimus Eluting Coronary Stent
- DEVICE TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,002 participants |
| Start Date | 2005-06 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
What the finished NCT00180479 record still lists
NCT00180479 is an interventional study that assigns participants to a tested intervention. Its 1,002 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 2 interventions - of which XIENCE V® Everolimus Eluting Coronary Stent is the first listed.
NCT00180479 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00180479 about?
NCT00180479 is a clinical study titled "SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)". This study is divided into 5 arms: 1. Randomized Clinical Trial (RCT): Prospective, randomized, active-controlled, single blind, parallel two-arm multi-center clinical trial in the United States (US) comparing XIENCE V® Everolimus Eluting Coronary Stent System (CSS) (2.5, 3.0, 3.5 mm diameter stent...
What is the current status of trial NCT00180479?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,002 participants. The study started on 2005-06. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00180479?
The interventions under investigation include: XIENCE V® Everolimus Eluting Coronary Stent (DEVICE), TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent (DEVICE).
Who is sponsoring clinical trial NCT00180479?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00180479's enrollment target sits among peer trials
1,002 295th of 2000 higher than 1,706 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia